599 related articles for article (PubMed ID: 34780478)
1. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.
Tong YH; Ding HY; Xin WX; Zhong LK; Xu GQ; Zhang B; Yang GN; Fang L
Tumori; 2022 Feb; 108(1):33-39. PubMed ID: 33511911
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Rudin CM; Awad MM; Navarro A; Gottfried M; Peters S; Csőszi T; Cheema PK; Rodriguez-Abreu D; Wollner M; Yang JC; Mazieres J; Orlandi FJ; Luft A; Gümüş M; Kato T; Kalemkerian GP; Luo Y; Ebiana V; Pietanza MC; Kim HR;
J Clin Oncol; 2020 Jul; 38(21):2369-2379. PubMed ID: 32468956
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer.
Meng M; Liu X; Liang X; Chen X; Li Y
Medicine (Baltimore); 2024 Apr; 103(16):e37836. PubMed ID: 38640325
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
[No Abstract] [Full Text] [Related]
6. First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
Lin S; Luo S; Gu D; Li M; Rao X; Wang C; Huang P; Xu X; Weng X
Oncologist; 2021 Nov; 26(11):e2013-e2020. PubMed ID: 34431578
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA.
Zeng X; Wan X; Peng L; Peng Y; Ma F; Liu Q; Tan C
BMJ Open; 2019 Dec; 9(12):e031019. PubMed ID: 31831534
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
[TBL] [Abstract][Full Text] [Related]
9. The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States.
Slater RL; Lai Y; Zhong Y; Li H; Meng Y; Moreno BH; Godwin JL; Frenkl T; Sonpavde GP; Mamtani R
J Med Econ; 2020 Sep; 23(9):967-977. PubMed ID: 32412387
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
Liao W; Huang J; Hutton D; Li Q
J Med Econ; 2019 Apr; 22(4):344-349. PubMed ID: 30646794
[TBL] [Abstract][Full Text] [Related]
11. First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis.
Zhu Y; Hu H; Ding D; Li S; Liao M; Shi Y; Huang J
Cost Eff Resour Alloc; 2021 Dec; 19(1):77. PubMed ID: 34863203
[TBL] [Abstract][Full Text] [Related]
12. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China.
Li LY; Wang H; Chen X; Li WQ; Cui JW
Chin Med J (Engl); 2019 Dec; 132(23):2790-2794. PubMed ID: 31856049
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
Zhou K; Zhou J; Huang J; Zhang N; Bai L; Yang Y; Li Q
Lung Cancer; 2019 Apr; 130():1-4. PubMed ID: 30885327
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland.
Bhadhuri A; Insinga R; Guggisberg P; Panje C; Schwenkglenks M
Swiss Med Wkly; 2019 Dec; 149():w20170. PubMed ID: 31880807
[TBL] [Abstract][Full Text] [Related]
17. First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective.
Hu X; Hay JW
Lung Cancer; 2018 Sep; 123():166-171. PubMed ID: 30089590
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.
Criss SD; Palazzo L; Watson TR; Paquette AM; Sigel K; Wisnivesky J; Kong CY
PLoS One; 2020; 15(1):e0228288. PubMed ID: 31995619
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.
Wang T; Li Y; Zheng X
BMC Health Serv Res; 2023 Jun; 23(1):691. PubMed ID: 37365540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
